- Home
- ZVSA
as 06-27-2025 12:34pm EST
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | SOMERVILLE |
| Market Cap: | 3.0M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.11 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.47 - $6.30 | Next Earning Date: | 08-08-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest ZyVersa Therapeutics Inc. News
ZVSA Breaking Stock News: Dive into ZVSA Ticker-Specific Updates for Smart Investing
MT Newswires
3 days ago
ZyVersa Therapeutics Says Phase 2a Study of Kidney Disease Treatment Activated
GlobeNewswire
3 days ago
ZyVersa Therapeutics Announces First Clinical Site Activation, Initiating Patient Recruitment for Cholesterol Efflux Mediator™ VAR 200’s Phase 2a Clinical Trial in Patients with Diabetic Kidney Disease (DKD)
GlobeNewswire
4 days ago
ZyVersa Therapeutics Announces Share Purchase Agreement for up to $10 Million in Partnership with Williamsburg Venture Holdings to Fund Clinical Development of Cholesterol Efflux Mediator™ VAR 200
GlobeNewswire
a month ago
ZyVersa Therapeutics Highlights Published Study Reinforcing That Microglia-driven Inflammation Is Pivotal in Development of Parkinson’s and Alzheimer’s Diseases
GlobeNewswire
2 months ago
ZyVersa Therapeutics Reports First Quarter 2025 Financial Results and Highlights Pipeline Progress
GlobeNewswire
2 months ago
ZyVersa Unveils Groundbreaking Potential of Inflammasome Inhibitors in Combination with GLP-1 Agonists to Address Unmet Medical Needs of People Living with Obesity; Provides R&D Update
GlobeNewswire
2 months ago
ZyVersa Therapeutics Announces Published Data Showing Inflammasome ASC Inhibitor IC 100 Decreases Microglial Inflammasome Activation and Alpha-Synuclein That Contribute to Neurodegeneration in Parkinson’s Disease
GlobeNewswire
2 months ago
ZyVersa Therapeutics CEO Issues Shareholder Letter Announcing Transformative R&D Trends for Inflammasome Inhibitors, and Provides Update on Inflammasome ASC Inhibitor IC 100’s Development Status
Compare ZVSA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ZVSA ZyVersa Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.